Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 6.9%

Adaptimmune Therapeutics plc (NASDAQ:ADAP)’s share price traded down 6.9% during mid-day trading on Wednesday . The company traded as low as $1.25 and last traded at $1.28. 463,988 shares were traded during mid-day trading, a decline of 74% from the average session volume of 1,790,984 shares. The stock had previously closed at $1.37.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Adaptimmune Therapeutics in a research note on Friday, December 29th. They issued a “hold” rating for the company.

Adaptimmune Therapeutics Stock Performance

The firm has a market cap of $1.28 billion, a PE ratio of -2.35 and a beta of 2.39. The firm’s 50-day moving average price is $1.42 and its two-hundred day moving average price is $0.91.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.12). Adaptimmune Therapeutics had a negative net margin of 188.90% and a negative return on equity of 155.39%. The business had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $4.80 million. As a group, sell-side analysts predict that Adaptimmune Therapeutics plc will post -0.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Several institutional investors have recently bought and sold shares of ADAP. Two Sigma Investments LP acquired a new position in Adaptimmune Therapeutics in the 4th quarter valued at $33,000. UBS Group AG grew its stake in shares of Adaptimmune Therapeutics by 1,090.8% during the 4th quarter. UBS Group AG now owns 23,625 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 21,641 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Adaptimmune Therapeutics by 56.4% during the 2nd quarter. Goldman Sachs Group Inc. now owns 48,077 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 17,332 shares during the period. Twin Focus Capital Partners LLC acquired a new position in shares of Adaptimmune Therapeutics during the 4th quarter worth $44,000. Finally, Barclays PLC acquired a new position in shares of Adaptimmune Therapeutics during the 2nd quarter worth $46,000. 31.37% of the stock is owned by institutional investors and hedge funds.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.